Atara Biotherapeutics (NASDAQ:ATRA) Stock Rating Lowered by RODMAN&RENSHAW

Atara Biotherapeutics (NASDAQ:ATRA) was downgraded by research analysts at RODMAN&RENSHAW from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other research analysts have also recently weighed in on ATRA. TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. Rodman & Renshaw initiated coverage on shares of Atara Biotherapeutics in a research note on Friday, December 20th. They set a “buy” rating and a $25.00 price target for the company. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday. Finally, Canaccord Genuity Group decreased their target price on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, January 17th. One analyst has rated the stock with a sell rating, three have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $17.75.

Atara Biotherapeutics Stock Up 13.9 %

NASDAQ:ATRA opened at $6.89 on Tuesday. Atara Biotherapeutics has a 12-month low of $5.40 and a 12-month high of $39.50. The stock’s fifty day simple moving average is $12.16 and its 200-day simple moving average is $9.97. The firm has a market capitalization of $39.69 million, a P/E ratio of -0.27 and a beta of 0.51.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating the consensus estimate of ($3.77) by $0.84. The firm had revenue of $40.19 million during the quarter, compared to the consensus estimate of $23.00 million. During the same period in the previous year, the company posted ($16.50) EPS. As a group, equities research analysts expect that Atara Biotherapeutics will post -9.86 earnings per share for the current year.

Institutional Trading of Atara Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ATRA. Geode Capital Management LLC lifted its stake in shares of Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 4,043 shares during the period. State Street Corp grew its stake in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 7,680 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Atara Biotherapeutics by 11.3% during the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after buying an additional 12,677 shares in the last quarter. FMR LLC increased its position in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Atara Biotherapeutics during the 2nd quarter worth approximately $79,000. 70.90% of the stock is currently owned by institutional investors and hedge funds.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.